← Back to Search

Transcutaneous CO2 Monitoring at Home for Children With Neuromuscular Disease

N/A
Waitlist Available
Led By Reshma Amin, MD
Research Sponsored by The Hospital for Sick Children
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a portable device that measures carbon dioxide levels in children with neuromuscular disorders while they sleep at home. The goal is to help doctors diagnose and treat breathing problems more quickly and efficiently.

Eligible Conditions
  • Sleep Apnea
  • Neuromuscular Diseases
  • Apnea
  • Neuromuscular Disease
  • Obstructive Sleep Apnea

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
a) Agreement of tcCO2 monitoring when worn in the ambulatory, at home, setting compared to tcCO2 recorded during a PSG in a hospital based sleep laboratory for diagnosis of nocturnal hypoventilation.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Transcutaneous CO2 monitoringExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcutaneous CO2 monitoring
2020
N/A
~130

Find a Location

Who is running the clinical trial?

The Hospital for Sick ChildrenLead Sponsor
711 Previous Clinical Trials
6,958,241 Total Patients Enrolled
2 Trials studying Neuromuscular Diseases
123 Patients Enrolled for Neuromuscular Diseases
Reshma Amin, MDPrincipal InvestigatorStaff Physician
2 Previous Clinical Trials
43 Total Patients Enrolled
~5 spots leftby Dec 2025